Examkin

Question

Difficulty: Very hardBias and Confounding in Research

An investigator is designing a prospective observational cohort study to evaluate the association between a newly approved CD40L-targeted monoclonal antibody and the development of severe opportunistic infections in patients with systemic lupus erythematosus (SLE). During the study's planning phase, the investigator identifies two critical variables that must be addressed:

1. High-dose corticosteroid use: The investigator notes that baseline high-dose corticosteroid use is associated with both a higher likelihood of being prescribed the new monoclonal antibody and an independently increased risk of opportunistic infections.
2. Baseline neutropenia: The investigator hypothesizes that the magnitude of the relative risk of opportunistic infections associated with the monoclonal antibody is significantly greater in patients with baseline neutropenia compared to those with normal neutrophil counts.

The investigator wishes to implement methodological and analytical strategies that will definitively remove the confounding effect of high-dose corticosteroid use, while simultaneously allowing for the formal statistical assessment of baseline neutropenia as an effect modifier.

Which of the following approaches would successfully accomplish BOTH of these objectives? (Select all that apply)

  1. Restricting the study cohort to patients who do not use high-dose corticosteroids, and performing a stratified analysis comparing the relative risks of infection between patients with and without baseline neutropeniaAnswer
  2. Adjusting for high-dose corticosteroid use as an independent covariate, and including an interaction term between monoclonal antibody use and baseline neutropenia in a multivariable regression modelAnswer
  3. C
    Including both high-dose corticosteroid use and baseline neutropenia strictly as independent covariates in a standard multivariable regression model, without incorporating interaction terms
  4. D
    Using propensity score matching to simultaneously balance both high-dose corticosteroid use and baseline neutropenia between the study groups, followed by reporting a single crude relative risk
  5. E
    Stratifying the analysis by high-dose corticosteroid use to control for its effects, and restricting the entire study population exclusively to patients with baseline neutropenia
  6. F
    Matching the exposed and unexposed groups based on baseline neutropenia during the design phase, and evaluating high-dose corticosteroid use as an interaction term in the final analysis

Answer

The correct approaches are restricting the cohort to non-corticosteroid users while stratifying by neutropenia, OR adjusting for corticosteroids as an independent covariate while using an interaction term for neutropenia.
The correct approaches must achieve two distinct methodological goals: control for the confounding effect of high-dose corticosteroids and evaluate statistical interaction (effect modification) by baseline neutropenia. Restriction (excluding patients on high-dose corticosteroids) effectively removes confounding during the study design phase. Subsequent stratification by baseline neutropenia allows the investigator to calculate and compare the relative risks in neutropenic versus non-neutropenic patients, successfully identifying effect modification. Alternatively, in the analysis phase, including high-dose corticosteroid use as an independent covariate adjusts for its confounding effect. Including an interaction term (monoclonal antibody × baseline neutropenia) in the multivariable regression model formally tests whether the effect of the antibody differs significantly depending on neutropenia status.

Step-by-Step Solution

1
Analyze the role of high-dose corticosteroid use.
It is associated with both the exposure (monoclonal antibody prescription) and the outcome (infections).
This establishes high-dose corticosteroid use as a classic confounder that must be controlled.
2
Analyze the role of baseline neutropenia.
The relative risk is hypothesized to differ based on its presence or absence.
This establishes baseline neutropenia as an effect modifier (statistical interaction) that must be formally evaluated.
3
Identify valid methods for controlling confounding.
Design phase: matching, restriction. Analysis phase: stratification, multivariable regression (as independent covariates), propensity scores.
These methods ensure the confounder does not distort the true association between exposure and outcome.
4
Identify valid methods for evaluating effect modification.
Analysis phase: stratified analysis (comparing measures of association between strata) or incorporating interaction terms in multivariable regression models.
These methods allow the investigator to test if the magnitude of the exposure's effect varies significantly across different levels of the third variable.
5
Evaluate the options against BOTH requirements simultaneously.
Only the option pairing restriction with stratification, and the option pairing independent covariate adjustment with an interaction term, meet both criteria.
The other options either treat both variables as confounders, restrict the effect modifier, or reverse the roles of the two variables entirely.

Key Concept

Methodological Handling of Confounding vs. Effect Modification
Estimated Time:2m 30s
Rate this question

Topics

Bias and Confounding in Research

More questions from this topic